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Urinary bladder cancer is the second most frequent tumor of the genitourinary tract [1]. The most common type of bladder cancer is urothelial carcinoma, 
also called transitional cell carcinoma, accounting for about 
90% of the cases. Other uncommon types, squamous cell 
carcinoma and adenocarcinoma, account for 3-7% and <2% 
of cases, respectively [2]. Bladder adenocarcinoma may be 
primary or secondary, with secondary being more common, 
involving the bladder by metastasis from the colon, prostate, 
endometrium, cervix, breast, and lung or by direct extension 
of adenocarcinoma of the surrounding organs, especially 
colorectum.
Primary bladder adenocarcinoma (PBA) is broadly classified 
as non-urachal and urachal adenocarcinoma based on location. 
Non-urachal PBA occurs in the posterior wall and trigone 
and urachal adenocarcinoma near dome and anterior wall of 
the bladder. Patients of PBA usually present in the sixth and 
seventh decades of life with male predominance [3]. The most 
common symptom is hematuria, followed by bladder irritation 
symptoms, and rarely, mucusuria. Risk factors include bladder 
exstrophy, schistosomiasis, chronic irritation, obstruction, and 
cystocele [4]. Morphologically, these tumors show glandular 
histology resembling colonic (enteric), mucinous, signet ring 
cell, clear cell, and mixed morphology. Therefore, distinguishing 
PBA from secondary involvement, especially, metastatic colonic 
adenocarcinoma (MCA) is often a diagnostic challenge by light 
microscopy alone. On immunohistochemistry (IHC), markers 
such as cytokeratin7 (CK), CK20, CDX2, and especially β-catenin 
have been found useful in resolving the differential diagnosis of 
these tumors [3].
CASE REPORT
A 55-year-old diabetic Indian female presented to surgical the 
outpatient department with complaints of hematuria for 5 months. 
There was no significant past history. Her general and systemic 
examination was unremarkable. Ultrasonography showed a 
hyperechoic urinary bladder mass with significant vascularity. 
Computed tomography scan showed an intraluminal mass in 
the anterior wall of the urinary bladder measuring 5 × 5 cm with 
anterior perivesical fat extension (Fig. 1). Urine cytology showed 
the presence of red blood cells along with few malignant cells. 
Hematological and biochemical parameters were within normal 
limits. The patient refused for total cystectomy, and thus, bladder 
growth resection was performed and sent for histopathological 
examination.
Grossly, tumor was solitary, polypoidal, gray-white with 
a circumference of 0.5 cm of normal bladder wall all around. 
Entire tumor was processed which, on microscopy, showed 
well-differentiated adenocarcinoma of enteric type comprising 
of glandular structures lined by columnar cells with basally 
located vesicular nuclei and prominent nucleoli. Tumor extension 
into perivesical fat was found microscopically (Fig. 2). No 
urothelial component was found. A panel of IHC was put which 
included CK7, CK20, carcinoembryonic antigen (CEA), cancer 
antigen-125 (CA), CDX2, GATA-3, and β-catenin. Our case 
showed nuclear positivity for CDX2, membranous positivity for 
β-catenin, focal positivity for CK20, and CEA and negativity for 
GATA-3, CK7, and CA-125 (Fig. 2). Based on these findings, 
a diagnosis of the enteric type of non-urachal primary urinary 
bladder adenocarcinoma (moderately differentiated) was made.
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DISCUSSION
Adenocarcinoma of the urinary bladder arising from the 
urothelial lining is an uncommon malignancy which accounts for 
0.5-2.0% of all malignant vesical tumors [2]. Adenocarcinoma 
of the bladder is reserved for tumor that is entirely composed 
of glandular differentiation, and thus, it is necessary to examine 
the entire tumor specimen to rule out any urothelial component 
before making the diagnosis of adenocarcinoma. Other potential 
metastatic adenocarcinomas (direct spread, lymphatic, and 
hematogenous) have to be ruled out before a diagnosis of primary 
adenocarcinoma of the urinary bladder is made. PBA occurs more 
frequently in schistosomiasis, endemic regions, and is associated 
with chronic irritation, obstruction, and cystocele. However, the 
present case had no known risk factors.
Grossly, bladder adenocarcinoma usually presents as a 
solitary lesion unlike urothelial carcinoma, which tends to be 
multifocal. It arises mostly from the trigone and posterior wall 
as a papillary, sessile, solid, or ulcerating lesion but can be found 
anywhere in the bladder [5]. The present case presented as a 
solitary, sessile polypoidal mass in the anterior wall of the urinary 
bladder. Histologically, bladder adenocarcinoma exhibits various 
growth patterns as follows: (a) Enteric (colonic or intestinal); 
(b) mucinous (colloid); (c) signet ring cell; (d) not otherwise 
specified (NOS); and (e) mixed patterns [6]. PBA is usually 
well to moderately differentiate and frequently of enteric type, 
comprising of glands lined by cuboidal to columnar cells with 
basal vesicular nuclei, prominent nucleoli, and apical cytoplasm 
with or without mucin vacuoles.
PBAs usually have associated surface glandular metaplasia, 
or cystitis glandular is in the surrounding urothelial lining. Since 
we received only tumor with a very small portion of surrounding 
normal bladder, we did not find areas of metaplasia or cystitis 
glandularis. The most important and challenging differential 
diagnosis is MCA which is virtually indistinguishable on 
histology as well as on routine IHC. Many PBAs have been 
reported to show a CK20+ and CK7− profile, similar to colonic 
adenocarcinomas as was found in our case [3]. Expression of 
CDX2 was thought to be diagnostic of colonic adenocarcinomas. 
However, the recent studies have shown the immunopositivity 
of CDX2 in vesical adenocarcinomas as well [7]. Our case 
also showed nuclear CDX2 positivity. However, unlike the 
usual cytoplasmic reactivity for GATA-3 in 60% of cases of 
PBA, our case was found to be negative. The role of β-catenin 
in differentiating PBA from MCA was first reported by Wang 
et al. in 2001 [3]. β-catenin is abnormally accumulated in the 
nucleus of tumor cells of colorectal adenocarcinomas due to 
impaired adenomatous polyposis coli- β-catenin interaction. 
Nuclear expression of β-catenin was observed in 81% of colonic 
adenocarcinomas metastatic to the bladder, and membranous 
staining pattern was observed in 88% of PBA. Our case showed 
a membranous pattern of positivity for β-catenin. Thus, nuclear 
versus membranous staining pattern of β-catenin is a good marker 
for the distinction between MCA and PBA.
The majority of patients with PBA have a muscle-invasive 
disease, and these patients are usually treated with radical 
cystectomy and pelvic lymph node dissection. Primary radiation 
therapy may be useful in patients who have non-resectable 
tumors. The traditional cisplatin-based chemotherapy that is 
used commonly for urothelial carcinoma has been found to be 
less effective in adenocarcinoma. Several studies have reported 
bladder adenocarcinoma to have a poorer clinical outcome 
than urothelial carcinoma. Our patient had been planned for 
chemotherapy for which she was non-compliant. However, she is 
currently free of metastasis, 5-month postsurgery.
CONCLUSION
PBA is a rare and aggressive malignant neoplasm of the 
urinary bladder that resembles MCA at the morphological and 
immunohistochemical level to some extent. Thus, complete 
clinical details in conjunction with a panel of antibodies 
comprising of β-catenin, CK20, CK7, and CDX2 can be helpful 
in distinguishing PBA from MCA.
Figure 1: Computed tomography scan showing intraluminal mass in 
anterior wall of urinary bladder
Figure 2: (a) Hematoxylin and eosin stained section of primary 
adenocarcinoma of urinary bladder (enteric type), (b) membranous 
positive staining for β-catenin, (c) nuclear-positive staining for 
CDX2, (d) negative staining for GATA-3
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